Avadel Pharmaceuticals (AVDL) EBITDA (2016 - 2021)
Historic EBITDA for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Q4 2021 value amounting to -$23.1 million.
- Avadel Pharmaceuticals' EBITDA fell 6224.4% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$85.5 million, marking a year-over-year decrease of 157112.64%. This contributed to the annual value of -$85.5 million for FY2021, which is 157112.64% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported EBITDA of -$23.1 million as of Q4 2021, which was down 6224.4% from -$25.7 million recorded in Q3 2021.
- Over the past 5 years, Avadel Pharmaceuticals' EBITDA peaked at $40.3 million during Q2 2020, and registered a low of -$75.4 million during Q4 2018.
- In the last 5 years, Avadel Pharmaceuticals' EBITDA had a median value of -$7.8 million in 2019 and averaged -$6.0 million.
- Per our database at Business Quant, Avadel Pharmaceuticals' EBITDA crashed by 174855.39% in 2018 and then surged by 100471.8% in 2020.
- Over the past 5 years, Avadel Pharmaceuticals' EBITDA (Quarter) stood at -$4.1 million in 2017, then tumbled by 1748.55% to -$75.4 million in 2018, then skyrocketed by 90.26% to -$7.3 million in 2019, then crashed by 94.09% to -$14.3 million in 2020, then plummeted by 62.24% to -$23.1 million in 2021.
- Its EBITDA was -$23.1 million in Q4 2021, compared to -$25.7 million in Q3 2021 and -$21.9 million in Q2 2021.